0

ADVERTISEMENT

Journal of Clinical Oncology Journal An American Society of Clinical Oncology Journal





OpenAthens/Shibboleth »

ACCESS PROVIDED BY VASTRA GOTALANDS REGIONEN

= MENU

<u>Journal of Clinical Oncology</u> > <u>List of Issues</u> > <u>Volume 38, Issue 15 suppl</u> >



CARE DELIVERY AND REGULATORY POLICY

The validity of VALID act: Cost modeling cancer diagnostics regulation by the FDA.



Richard Huang, Laura Lasiter, Christina Young, Jeff Allen, Jochen K Lennerz

Show Less

Massachusetts General Hospital, Boston, MA; Friends of Cancer Research, Washington, DC

Abstract Disclosures

Abstract

e14124

Background: VALID Act is a bipartisan draft legislation proposing to ensure the quality and safety of diagnostic tests through direct FDA

OPTIONS & TOOLS

Export Citation

Track Citation

Add To Favorites

Rights & Permissions

ADVERTISEMENT

ADVERTISEMENT

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI:

10.1200/JCO.2020.38.15_suppl. *Journal of Clinical Oncology* 38, no. 15_suppl

Published online May 25, 2020.

WE RECOMMEND

oversight. Currently, FDA exercises enforcement discretion and exempts from premarket review tests that are developed and used in the same clinical laboratory. Many stakeholders have pointed out that the lack of direct FDA oversight has led to erroneous results that have serious patient consequences. However, the maintenance cost after the implementation of the Act is unknown. Thus, we estimate the additional financial burden of genotyping all new late stage cancer patients under a fully implemented VALID Act precertification framework. Methods: Based on our laboratory with 36 high-complexity clinical assays, we modeled the cost increase by dividing the total anticipated cost for annual FDA precertification by our 2019 patient volume. To model the stringency of complying with the Act, we calculated either 3, 6, or 9 assays as representative of the laboratory's test complexity. To make the estimated additional annual national healthcare cost relatable, we expressed the increase as a distributed cost per newly diagnosed late stage cancer patient in 2019 (NCI SEER) or per employed person in 2019 (Bureau of Labor Statistics). Results: FDA precertification for 3 assays was estimated at \$638,310.13, or when divided by our annual late stage patient volume (n = 10,232), an increased cost of \$62.38/patient. Precertification for 6 or 9 assays costs \$684,751.60 (+\$66.92/patient) or \$1,253,717.25 (+\$122.53/patient), respectively. If only 1 cancer center per state/DC/PR got precertified (n = 52), multiplied by the cost of precertifying 3 assays, then the annual national healthcare cost would increase by \$33,192,126.50, or +\$42.37/new late stage patient (n = 783,476) or +\$0.21/employed (n = 158,803,000). Precertification for 52 centers for 6 or 9 assays would cost \$35,607,083.20 (+\$45.45/patient, +\$0.22/employed) or \$65,193,297.00 (+\$83.21/patient, +\$0.41/employed), respectively. Nationally, there are ~886 centers and the increased cost was estimated at < \$7/employed. Even though

AACR Issues Statement to Applaud FDA's Actions By The ASCO Post, The ASCO Post, 2014

Evidence From Ghana Indicates That Childhood Cancer Treatment in Sub-Saharan Africa Is Very Cost Effective: A Report From the Childhood Cancer 2030 Network

Lorna Renner et al., JCO Global Oncology, 2018

Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists Rena M. Conti et al., J Clin Oncol, 2013

Mammography Has Led to Fewer Late-Stage Breast Cancers, Study Finds By The ASCO Post, The ASCO Post, 2014

Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare

Joshua A. Roth et al., JCO Oncology Practice, 2015

In Brief This Week: Veracyte, Natera, VolitionRx, and More

Leo O'Connor et al., 360Dx, 2019

Proposed FDA Regulation of LDTs Could Impact Labs' Ability to Alter Test Assays

Adam Bonislawski, 360Dx, 2020

FDA Grants IDE Approval for Almac Diagnostic Services' CDx for Use in Cancer Drug Study

Precision Oncology News, 2019

US Medical Cancer Care Costs Substantial, Expected to Increase Cancer Therapy Advisor, 2020 the VALID Act will affect more than late stage cancer patients, thus costs will vary, our data show how a specific change of the Act will impact oncology practice. **Conclusions:** We provided a concrete cost model for late stage cancer patients under the proposed VALID Act. Cost modeling is important in informing the balanced legislative language needed to ensure patient access to validated cancer diagnostics, while supporting continued innovation by clinical laboratories.

© 2020 American Society of Clinical Oncology

Research Sponsor:

None

Adolescent Patients With 2 Different Types Of Vaccines. US HCPs.

Sponsored By GSK

Powered by TREND MD

WHAT'S POPULAR

Most Read

Most Cited

Venous
Thromboembolism
Prophylaxis and
Treatment in Patients
With Cancer: ASCO
Clinical Practice
Guideline Update
Key et al.

Management of
Immune-Related Adverse
Events in Patients
Treated With Immune
Checkpoint Inhibitor
Therapy: American
Society of Clinical
Oncology Clinical Practice
Guideline
Brahmer et al.

Prognostic Index for
Acute- and LymphomaType Adult T-Cell
Leukemia/Lymphoma
Katsuya et al.

Updated Analysis From
KEYNOTE-189:
Pembrolizumab or
Placebo Plus Pemetrexed
and Platinum for
Previously Untreated
Metastatic
Nonsquamous NonSmall-Cell Lung Cancer
Gadgeel et al.

Abemaciclib Combined
With Endocrine Therapy
for the Adjuvant
Treatment of HR+,
HER2-, Node-Positive,

<u>High-Risk, Early Breast</u> <u>Cancer (monarchE)</u> Johnston et al.



Content

Newest Articles Archive Meeting Abstracts

Journal Information

About Editorial Roster Contact Us Permissions

Resources

Authors Reviewers Subscribers Institutions Advertisers

Submit Your Manuscript

Subscribe to this Journal



ASCO FAMILY OF SITES

Journals

Journal of Clinical
Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer
Informatics
JCO Precision Oncology

Publications

ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post JCO OP DAIS


Education

ASCO eLearning ASCO Meetings Cancer.Net

Other Sites

ASCO.org
ASCO Author Services
ASCO Career Center
CancerLinQ
Conquer Cancer
Foundation
TAPUR Study













Terms of Use | Privacy Policy | Cookies